Advanced Materials · 2018 · 356 citations · 37 references
PharmacyBiomedical EngineeringOncologyBiomaterialsDrug DeliveryNanoparticle Drug DeliveryCancer NanomedicineDrug EncapsulationNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsProtein DeliveryMesoporous Silica NanomaterialsMesoporous Silica NanoparticlesNanoparticle DeliveryNucleic Acid TherapeuticsPoresSilica-based NanoparticlesTumor-targeted Drug DeliveryTumor-targeted Encapsulation
Controlled delivery of protein therapeutics remains a challenge. The study reports the design of biodegradable mesoporous silica nanoparticles incorporating diselenide bonds for oxidative and redox dual‑responsive protein delivery. The nanoparticles encapsulate RNase A electrostatically in 8‑10 nm pores and release it upon oxidative or redox‑induced degradation, while cancer‑cell membrane cloaking provides homologous targeting and immune‑invasion properties. In vitro and in vivo studies show that the cell‑membrane‑coated, dual‑responsive degradable MSNs enhance circulation time, tumor accumulation, and anti‑cancer efficacy with low toxicity, indicating promise for protein and nucleic acid delivery.
Controlled delivery of protein therapeutics remains a challenge. Here, the inclusion of diselenide-bond-containing organosilica moieties into the framework of silica to fabricate biodegradable mesoporous silica nanoparticles (MSNs) with oxidative and redox dual-responsiveness is reported. These diselenide-bridged MSNs can encapsulate cytotoxic RNase A into the 8-10 nm internal pores via electrostatic interaction and release the payload via a matrix-degradation controlled mechanism upon exposure to oxidative or redox conditions. After surface cloaking with cancer-cell-derived membrane fragments, these bioinspired RNase A-loaded MSNs exhibit homologous targeting and immune-invasion characteristics inherited from the source cancer cells. The efficient in vitro and in vivo anti-cancer performance, which includes increased blood circulation time and enhanced tumor accumulation along with low toxicity, suggests that these cell-membrane-coated, dual-responsive degradable MSNs represent a promising platform for the delivery of bio-macromolecules such as protein and nucleic acid therapeutics.
37
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Ronnie H. Fang, Che‐Ming Jack Hu, Brian T. Luk et al. · Nano Letters · 2014 · 1.5K citations · Full text
Pharmacy, Immunology, Pharmaceutics +17
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Yoko Kojima, Jens-Peter Volkmer, Kelly M. McKenna et al. · Nature · 2016 · 656 citations · Full text
Life Sciences, Immunology, Pathology +14
Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors
Huiping Sun, Jinghan Su, Qingshuo Meng et al. · Advanced Materials · 2016 · 647 citations
Cancer Cell Membrane‐Coated Upconversion Nanoprobes for Highly Specific Tumor Imaging
Lang Rao, Lin‐Lin Bu, Bo Cai et al. · Advanced Materials · 2016 · 530 citations
Medicine, Cancer Biology, Oncology +11